Featured Stories
Royal Marsden NHS Foundation Trust: World-First Approach to Precision Diagnostics in Multiple Myeloma Care
LONDON, England, Oct. 31 -- The Royal Marsden National Health Service Foundation Trust issued the following news:
* * *
A world-first approach to precision diagnostics in multiple myeloma care
The Royal Marsden is advancing precision diagnostics and shaping the future of myeloma care with the launch of MyTrack(TM) Myeloma
30 October 2026
Written by Dr Kevin Boyd, Consultant Haematologist, The Royal Marsden
Multiple myeloma is a complex and highly variable cancer, as the disease can behave differently from one individual to another. This variability presents a fundamental challenge: how do
... Show Full Article
LONDON, England, Oct. 31 -- The Royal Marsden National Health Service Foundation Trust issued the following news:
* * *
A world-first approach to precision diagnostics in multiple myeloma care
The Royal Marsden is advancing precision diagnostics and shaping the future of myeloma care with the launch of MyTrack(TM) Myeloma
30 October 2026
Written by Dr Kevin Boyd, Consultant Haematologist, The Royal Marsden
Multiple myeloma is a complex and highly variable cancer, as the disease can behave differently from one individual to another. This variability presents a fundamental challenge: how dowe ensure that each patient receives care that is truly tailored to their disease biology and personal circumstances?
This is where precision diagnostics has the potential to transform the diagnostic and treatment pathway. The Royal Marsden's MyTrack(TM) Myeloma is a ground-breaking, advanced diagnostic solution designed to enable personalised treatment and improve patient outcomes.
From innovation to clinical impact
The development of MyTrack(TM) Myeloma represents a significant step forward in the management of this condition. It combines standard diagnostic testing with three innovative, personalised genomic and disease-monitoring tests within a single integrated pathway. This world-first diagnostic framework supports decision-making across the entire patient journey, from diagnosis through to long-term disease monitoring.
At diagnosis, enhanced tumour profiling allows us to more accurately identify patients with aggressive disease. This enables clinicians to adapt treatment strategies earlier and, if needed, escalate the approach from the outset.
Later in the pathway, highly sensitive minimal residual disease tracking provides a deeper understanding of how well a patient is responding to treatment. This long-term monitoring of remission depth can inform whether planned treatment breaks are a safe and evidence-based possibility for suitable patients.
Enabling a new era of personalised myeloma care
For people living with myeloma, the 'one-size-fits-all' continuous therapy approach can carry both physical and psychological impacts. Patients may experience ongoing side effects, and the need for long-term therapy can reduce quality of life.
The possibility of a treatment-free interval, when clinically appropriate, is highly meaningful. However, implementing this safely requires a level of precision that has previously been challenging.
MyTrack(TM) Myeloma addresses this gap. By combining detailed risk profiling with highly sensitive monitoring, it can provide clinicians and patients with the confidence to make more personalised and informed decisions. As a result, care can be tailored to the biology of the disease, the response depth of the patient, as well as their individual priorities.
Driving global leadership in myeloma care
The pathway is designed through years of clinical research leadership at The Royal Marsden, translating insights from world-renowned haematology experts and leading clinical studies into a new approach of how precision diagnostics can be applied in practice.
The Royal Marsden is committed to leading change and advancing international guidelines and clinical standards that will define how myeloma is managed for years to come.
I believe that patient outcomes can be improved by using this pathway and the ambition is for MyTrack(TM) Myeloma to become the gold standard for anyone diagnosed with multiple myeloma.
Supporting clinicians, empowering patients
MyTrack(TM) Myeloma is currently available for private patients and has been designed to integrate seamlessly with local care. By sending the patient's bone marrow and blood sample, referring clinicians will receive a comprehensive, integrated, expert-led report that combines all the diagnostic insights into a clear, concise format. This supports individualised care and enables more effective, evidence-based shared decision-making.
Ultimately, our goal is to improve the outcomes and quality of life for people living with myeloma, and with this pathway, patients can receive advanced, individualised care.
MyTrack(TM) Myeloma is initially available to private patients, but The Royal Marsden's ambition is to work with the NHS to bring this pioneering pathway to more patients in the future.
Explore our MyTrack(TM) Myeloma service page (https://www.royalmarsden.nhs.uk/services/mytrack-myeloma) to learn more about the pathway, watch our video FAQs and find out how to contact the team.
* * *
Original text here: https://www.royalmarsden.nhs.uk/news-and-events/news/world-first-approach-precision-diagnostics-multiple-myeloma-care
RSE President Responds to UK Autumn Budget 2026
EDINBURGH, Scotland, Oct. 31 -- The Royal Society of Edinburgh issued the following news:
* * *
30 October 2026
RSE President responds to UK Autumn Budget 2026
Responding to the UK Government's Autumn Budget, Professor Sir Anton Muscatelli FRSE, President of the Royal Society of Edinburgh, said:
"We welcome the UK Government's recognition of the importance of research and innovation to economic growth and national prosperity, including new investment in technologies and capabilities in which Scotland has considerable strengths.
"However, investment in innovation must go hand in hand with
... Show Full Article
EDINBURGH, Scotland, Oct. 31 -- The Royal Society of Edinburgh issued the following news:
* * *
30 October 2026
RSE President responds to UK Autumn Budget 2026
Responding to the UK Government's Autumn Budget, Professor Sir Anton Muscatelli FRSE, President of the Royal Society of Edinburgh, said:
"We welcome the UK Government's recognition of the importance of research and innovation to economic growth and national prosperity, including new investment in technologies and capabilities in which Scotland has considerable strengths.
"However, investment in innovation must go hand in hand withsustained support for fundamental, curiosity-driven research. The discoveries that underpin tomorrow's economic and societal advances often emerge from research whose applications cannot be predicted in advance. A strong and financially sustainable university sector is essential to this endeavour.
"For Scotland, the picture is particularly complex. Our research and innovation ecosystem operates across both UK-wide and devolved funding arrangements, and the implications of this Budget will need to be considered alongside the forthcoming Scottish Budget and the decisions that follow.
"As Scotland's National Academy, the RSE will continue to champion the value of research across all disciplines, and the importance of ensuring that investment in knowledge and innovation delivers lasting benefits for communities, businesses and society throughout Scotland."
* * *
Original text here: https://rse.org.uk/rse-president-responds-to-uk-autumn-budget-2026/
Treatment = Life: AHF Reaches 2 Million Patients in Care in Africa
LOS ANGELES, California, Oct. 30 -- The AIDS Healthcare Foundation posted the following news:
* * *
Treatment = Life: AHF Reaches 2 Million Patients in Care in Africa
*
AIDS Healthcare Foundation (AHF) has surpassed 2 million patients in care across 15 African countries, marking a historic achievement 25 years after beginning its first programs outside the United States in South Africa and Uganda. With programs in four additional countries expected to launch in 2027, AHF is recognizing the communities and partnerships behind this progress while calling for urgent action to close persistent
... Show Full Article
LOS ANGELES, California, Oct. 30 -- The AIDS Healthcare Foundation posted the following news:
* * *
Treatment = Life: AHF Reaches 2 Million Patients in Care in Africa
*
AIDS Healthcare Foundation (AHF) has surpassed 2 million patients in care across 15 African countries, marking a historic achievement 25 years after beginning its first programs outside the United States in South Africa and Uganda. With programs in four additional countries expected to launch in 2027, AHF is recognizing the communities and partnerships behind this progress while calling for urgent action to close persistentgaps in the HIV response.
AHF's work in Africa began in 2001 with modest programs when antiretroviral therapy was beyond the reach of most people on the continent. At the time, only about 5% of the 21 million patients in need were receiving treatment. Combining direct care with advocacy for affordable medicines, AHF worked alongside governments and communities to help make lifesaving treatment accessible.
The milestone brings AHF's "Treatment = Life" message into focus: HIV treatment is prevention. People who achieve viral suppression do not transmit HIV. Treatment keeps people alive, healthy, and able to pursue their futures. These benefits require early diagnosis, prompt treatment, and uninterrupted care.
"Two million patients in care means millions more family and community members whose lives are better because their loved ones are alive and thriving," said Dr. Penninah Iutung, AHF Executive Vice President - Global. "By keeping people healthy, antiretroviral treatment helps them live fulfilling lives--strengthening productivity, household incomes, and communities' social and economic wellbeing. That is what 'Treatment = Life' means, and it is what makes this milestone so meaningful."
Yet testing is still lagging, prevention remains off track, and too many people go without treatment or fall out of care. These practical gaps threaten progress and demand renewed political commitment.
"This progress took activism, research, political will, and people working together--from communities to governments--because they refused to accept that millions should die without treatment," said Martin Matabishi, AHF Africa Bureau Chief. "We must reaffirm our commitment to the HIV response. We must reach people who do not know their HIV status, expand prevention, and ensure everyone who starts treatment stays on it. HIV is not over."
AHF calls on governments and partners to protect the gains made in the HIV response by sustaining HIV funding, expanding testing and prevention services, ensuring uninterrupted antiretroviral therapy (ART) access and retaining patients in care. "Treatment = Life" embodies AHF's commitment to supporting Africa's efforts to advance the AIDS response and achieve the goal of HIV control.
***
Original text here: https://www.aidshealth.org/2026/10/treatment-life-ahf-reaches-2-million-patients-in-care-in-africa/
Public Comments Overwhelmingly Support Menhaden Reforms in Chesapeake Bay
ANNAPOLIS, Maryland, Oct. 30 -- The Chesapeake Bay Foundation posted the following news release:
* * *
Public Comments Overwhelmingly Support Menhaden Reforms in Chesapeake Bay
*
Pressure is mounting while a major fisheries panel prepares to consider much-needed reductions to the Chesapeake Bay industrial menhaden harvest, as public comments released this week show the vast majority support significant new limits.
The newly released data, ahead of an expected vote on the new limits next month, comes as members of Congress are calling on the Atlantic States Marine Fisheries Commission (ASMFC)
... Show Full Article
ANNAPOLIS, Maryland, Oct. 30 -- The Chesapeake Bay Foundation posted the following news release:
* * *
Public Comments Overwhelmingly Support Menhaden Reforms in Chesapeake Bay
*
Pressure is mounting while a major fisheries panel prepares to consider much-needed reductions to the Chesapeake Bay industrial menhaden harvest, as public comments released this week show the vast majority support significant new limits.
The newly released data, ahead of an expected vote on the new limits next month, comes as members of Congress are calling on the Atlantic States Marine Fisheries Commission (ASMFC)to act on menhaden.
Public comments on proposed changes to menhaden reduction fishing in the Chesapeake Bay overwhelmingly supported options that would reduce the menhaden harvest within the Bay and distribute it throughout the season to protect predators and reduce conflict with bait fisheries, according to data released by the ASMFC.
The commission received more than 48,000 comments on the proposal, known as Draft Addendum II, during the public comment period that ran from August 27-October 9. All told, more than 42,000 comments favored options that would result in significant cuts to the harvest and would impose new quota periods.
The Chesapeake Bay Foundation (CBF) supports the strongest options on the table, which include:
* Cutting the Chesapeake Bay Reduction Fishery Cap in half
* Setting the Cap based on the coastwide catch limit
* Creating three quota periods to better spread the harvest out throughout the season
These conservation measures would leave more menhaden in the water to support the Chesapeake Bay ecosystem and bolster struggling predators and communities that depend on this critical forage fish.
More than 24,000 people signed on to support CBF's official public comment letter, while an additional 17,000 commenters echoed support for this option.
Members of Congress from states along the Atlantic Coast have similarly weighed in to support new regulations. In Maryland, a group of 29 bipartisan state legislators and the Annapolis City Council supported major conservation-minded menhaden reforms.
"Annapolis relies on the Chesapeake Bay, and the Chesapeake Bay relies on menhaden--as one of the key foundations of its food chain," said Alderman Harry Huntley, a sponsor of the Annapolis resolution.
"The City Council was happy to do our part by calling on the ASMFC to cut the Bay cap by 50% and implement other important conservation measures."
Menhaden are a key fish in marine food chains, feeding osprey, striped bass, and other wildlife. The menhadenreduction fishery is an industrial operation concentrated in the Virginia waters of the Chesapeake Bay, where a fleet of vessels catches more than 100 million pounds of the fish each year.
The reforms the ASMFC is considering respond to worsening concerns tied to menhaden availability in the Bay, including starving osprey chicks and plummeting catches for watermen who use menhaden for bait.
As these warning signs escalate, 92 percent of Virginia voters support leaving more menhaden in the Bay, according to recent polling.
The ASMFC is expected to consider the proposed changes on Nov. 10-11 at the commission's annual meeting.
Chesapeake Bay Foundation Forage Campaign Manager Will Poston issued the following statement:
"The public has spoken. They're demanding that the ASMFC act to conserve menhaden in the Chesapeake Bay.
"Up and down the Atlantic Coast, concerned residents, anglers, birders, and lawmakers are likewise calling for strengthening menhaden protections in the Chesapeake Bay. By adopting the strongest options in Draft Addendum II, ASMFC can relieve pressure on this struggling estuary by leaving more menhaden in the water to support the Bay, the fish and wildlife, and the communities that depend on a healthy menhaden population."
***
Original text here: https://www.cbf.org/news/public-comments-overwhelmingly-support-menhaden-reforms-in-chesapeake-bay/ (TNSmlt)
OMRF wins four top honors from Society of Professional Journalists
OKLAHOMA CITY, Oklahoma, Oct. 30 -- The Oklahoma Medical Research Foundation posted the following news:
* * *
OMRF wins four top honors from Society of Professional Journalists
*
The Oklahoma Medical Research Foundation took home top honors in four categories at the Society of Professional Journalists Oklahoma Pro Chapter's 2026 awards last week in Tulsa.
The competition included more than 550 entries across all categories from organizations and media outlets throughout Oklahoma. Journalists and other media professionals from Pennsylvania served as judges.
OMRF's magazine, Findings, received
... Show Full Article
OKLAHOMA CITY, Oklahoma, Oct. 30 -- The Oklahoma Medical Research Foundation posted the following news:
* * *
OMRF wins four top honors from Society of Professional Journalists
*
The Oklahoma Medical Research Foundation took home top honors in four categories at the Society of Professional Journalists Oklahoma Pro Chapter's 2026 awards last week in Tulsa.
The competition included more than 550 entries across all categories from organizations and media outlets throughout Oklahoma. Journalists and other media professionals from Pennsylvania served as judges.
OMRF's magazine, Findings, receivedfirst place in the category of outstanding public relations publication. The foundation publishes Findings twice a year for more than 30,000 supporters. The winning issue, which celebrated the 35th anniversary of Findings, marked the fifth time the magazine has received top honors in this category.
Judges called the issue "a creative, moving approach to humanize the work that is done every day. The profiles were skillfully done, well-written, and impactful. Very moving!"
"The Threat to Medical Research," a Findings story about the impact of grant cancellations, delays and widespread layoffs at the National Institutes of Health, also earned the top prize in feature writing.
The magazine also captured first place in the graphics category for the cover of its 35th anniversary issue.
The foundation's annual appeal to donors, "Powering Discovery," won for outstanding public relations campaign. Judges wrote that OMRF's entry "stood out for its powerful storytelling and exceptional strategic execution."
The appeal wove together the story of two donors - one with Alzheimer's - with an OMRF scientist's research on the disease.
The result, judges said, was "a narrative that was both urgent and profoundly human."
***
Original text here: https://omrf.org/omrf-wins-four-top-honors-from-society-of-professional-journalists/
Meet Ari: Foundation Launches Partnership with Citizen Health
DANVERS, Massachusetts, Oct. 30 -- The National Scleroderma Foundation posted the following news:
* * *
Meet Ari: Foundation Launches Partnership with Citizen Health
*
Most people with autoimmune conditions already keep their own records: a spreadsheet of results, a running list of medicines and who prescribed them, or notes typed into a phone in the parking lot before an appointment.
It is a lot of documentation. It is a lot of work.
The National Scleroderma Foundation is proud to launch a partnership with Citizen Health to make that work a lot easier. Meet Ari, the AI teammate for your
... Show Full Article
DANVERS, Massachusetts, Oct. 30 -- The National Scleroderma Foundation posted the following news:
* * *
Meet Ari: Foundation Launches Partnership with Citizen Health
*
Most people with autoimmune conditions already keep their own records: a spreadsheet of results, a running list of medicines and who prescribed them, or notes typed into a phone in the parking lot before an appointment.
It is a lot of documentation. It is a lot of work.
The National Scleroderma Foundation is proud to launch a partnership with Citizen Health to make that work a lot easier. Meet Ari, the AI teammate for yourscleroderma journey.
Ari takes the lead and helps you manage everything you need to know about your care.
Keeps records from all your specialists together in one place you control, so results from each appointment are ready for the next
Keeps your history, medicines, and care team information ready to share with each new doctor--even those unfamiliar with your condition--so you only need to tell your story once
Tracks your key symptoms between appointments in your own words, so you can share an accurate picture of how you've been feeling
Reads an insurance denial, drafts the appeal, and files it with your approval
Gets benefits and work paperwork started early, since approvals often take longer than expected
Helps you prepare questions for each appointment and stay on top of follow-ups
Work with Ari through text messages, so there is no app to download and no new portal to remember. You can use voice memos on a hard day, type your notes on a good one, or send a photo of a results letter or an insurance form. Ari flags what needs your attention without prompting and always asks for your approval before taking action.
Visit the dedicated landing page for the National Scleroderma community: https://scleroderma.org/Ari. Ready to learn more? Register for our upcoming webinar with the team from Citizen Health who will go in-depth on what you can expect when you team up with Ari.
***
Original text here: https://scleroderma.org/meet-ari-foundation-launches-partnership-with-citizen-health/ (TNSmlt)
Conservation Lands Foundation Opposes Bipartisan American Affordability and Jobs Act
DURANGO, Colorado, Oct. 30 -- The Conservation Lands Foundation issued the following news:
* * *
The Conservation Lands Foundation Opposes Bipartisan American Affordability and Jobs Act
October 29, 2026
Proposal as written decimates core cultural and environmental safeguards.
-
WASHINGTON, D.C. - After careful review of the recently introduced S.5653 the Bipartisan American Affordability and Jobs Act, the Conservation Lands Foundation opposes the bill as written because it would weaken core cultural resource and environmental safeguards that protect the integrity of the National Conservation
... Show Full Article
DURANGO, Colorado, Oct. 30 -- The Conservation Lands Foundation issued the following news:
* * *
The Conservation Lands Foundation Opposes Bipartisan American Affordability and Jobs Act
October 29, 2026
Proposal as written decimates core cultural and environmental safeguards.
-
WASHINGTON, D.C. - After careful review of the recently introduced S.5653 the Bipartisan American Affordability and Jobs Act, the Conservation Lands Foundation opposes the bill as written because it would weaken core cultural resource and environmental safeguards that protect the integrity of the National ConservationLands -- the 38-million-acre system of national monuments, national conservation areas, wilderness, wilderness study areas, wild and scenic rivers, and national trails managed by the Bureau of Land Management (BLM).
"While the bill does not mention the National Conservation Lands by name and contains no Federal Land Policy and Management Act (FLPMA) amendments, its procedural rewrites would apply directly to BLM authorizations and impact treasured landscapes, including future additions to the National Conservation Lands," said Chris Hill, CEO of the Conservation Lands Foundation, which represents a nonpartisan, national network of community advocates solely focused on the public lands overseen by the Bureau of Land Management.
"If the proposal were to pass in its current form, it would result in cursory review of impacts to cultural resources and Tribal cultural values on public lands during environmental review of industrial projects; allow the federal government to rubber stamp destructive projects on landscapes without sufficient analysis of the impacts on wildlife and communities; and remove options for the public to engage in the process.
"Our nation's public lands have faced countless assaults during this Congressional session. We should be strengthening safeguards to prevent future attacks instead of widening loopholes to be exploited for private gain. Therefore, the Conservation Lands Foundation opposes S. 5653 in its current form and urges Congress not to advance it without removing or fundamentally revising the Historic Preservation title and several other sections which weaken meaningful cultural resource consultation, science-based environmental review, and endangered species safeguards for the National Conservation Lands," said Hill.
* * *
Original text here: https://www.conservationlands.org/the-conservation-lands-foundation-opposes-bipartisan-american-affordability-and-jobs-act
